A receptor tyrosine-protein kinase erbB-2 also known as epidermal growth factor receptor 2 (HER2) is over-expressed in many cancers including breast, ovarian, and gastric cancers, and heterodimerization of this initiates various signaling pathways leading to aggressive proliferation and tumorigenesis [1], thus becoming a well-known therapeutic target in cancer research over 30 years [2]. Here, ERBB2 is linked to gastric cancer.